Saadet KADER, Gulhan AKSOY SARAÇ, Aynure ÖZTEKİN, Unsal SAVCI, Engin ŞENEL, Coskun ÖZTEKİN, Turan AKDAĞ, Salim NEŞELİOĞLU, Ozcan EREL

The utility of ischemia modified albumin as an oxidative stress biomarker in seborrheic dermatitis

Aim: Seborrheic dermatitis (SD) is a commonly seen chronic inflammatory skin disease that occurs as scaly reddish-brown itchy patches on sebaceous, gland-rich areas of the scalp, face, and trunk. The relation between SD disease and serum IMA (Ischemia modified albumin) levels remains unknown. To investigate the potential role of serum IMA and corrected IMA levels in SD disease. Materials and Methods: Thirty-seven participants who were diagnosed with SD disease and sixty-two healthy subjects (control group) were enrolled in the study. Venous blood samples were collected from each participant, and serum IMA was measured spectrophotometrically using the albumin cobalt binding test. Results: The serum IMA and corrected IMA levels were statistically significant between the groups, and the levels of IMA and corrected IMA were measured as SD patients group 0.70, 0.70 and control group 0.52, 0.51 ABSU (absorbance units), respectively (p < 0.05). Moreover, serum IMA and corrected IMA levels were statistically significant between male and female groups in terms of gender as 0.75 and 0.69 ABSU, respectively (p < 0.05). Serum albumin levels, age, and BMI (body mass index) were statistically insignificant between these groups. Conclusion: Our results show increased serum IMA and corrected IMA levels in patients with SD. Evaluation of IMA and corrected IMA levels in SD disease may contribute to diagnosis and prognosis. Further and comprehensive studies are needed

PDF

___

1. Cheong WK, Yeung CK, Torsekar RG, Suh DH, Ungpakorn R, Widaty S et al: Treatment of Seborrhoeic Dermatitis in Asia: A Consensus Guide. Skin Appendage Disord 2015; 1: 187-196.
2. Palamaras I, Kyriakis KP, Stavrianeas NG. Seborrheic dermatitis: lifetime detection rates. J Eur Acad Dermatol Venereol 2012; 26: 524-6.
3. Bukvic Mokos Z, Kralj M, Basta-Juzbašic A, Lakoš Jukic I. Seborrheic dermatitis: an update. Acta Dermatovenerol Croat 2012; 20: 98-104.
4. Sampaio AL, Mameri AC, Vargas TJ, Ramos-e-Silva M, Nunes AP, Carneiro SC. Seborrheic dermatitis. An Bras Dermatol 2011; 86: 1061-74.
5. Lee P, Wu X. Review: modifications of human serum albumin and their binding effect. Curr Pharm Des 2015; 21(14): 1862-5.
6. CoverdaleJ PC, Katundu KGH, Sobczak AIS, Arya S, Blindauer CA, Stewart AJ. Ischemia-modified albumin: Crosstalk between fatty acid and cobalt binding. Prostaglandins Leukot Essent Fatty Acids 2018 Aug; 135: 147-157.
7. Oran I, Oran B. Ischemia-Modified Albumin as a Marker of Acute Coronary Syndrome: The Case for Revising the Concept of "N-Terminal Modification" to "Fatty Acid Occupation" of Albumin. Dis Markers 2017; 2017: 5692583.
8. Özdemir M, Kiyici A, Balevi A, Mevlitoglu I. and Peru C. Assessment of ischaemia-modified albumin level in patients with psoriasis. Clinical and Experimental Dermatology 2012; 37: 610- 614.
9. Dessinioti C, Katsambas A. Seborrheic dermatitis: etiology, risk factors, and treatments: facts and controversies. Clinics in Dermatology 2013; 31, 343-351.
10. Fritsch PO, Reider N. Other eczematous eruptions. Dermatology. New York: Mosb 2003; (1): 215-26.
11. Gupta AK, Bluhm R. Seborrheic dermatitis. J Eur Acad Dermatol Venereol 2004 ;18: 13-26.
12. Misery L, Touboul S, Vinçot C, Dutray S, Rolland-Jacob G, Consoli SG et al. Stress et dermatite séborrhéique [Stress and seborrheic dermatitis]. Ann Dermatol Venereol. 2007 Nov; 134(11): 833-7.
13. Cömert A, Akbas B, Kılıç EZ et al. Psychiatric comorbidities and alexithymia in patients with seborrheic dermatitis: a questionnaire study in Turkey. American Journal of Clinical Dermatology. 2013 Aug; 14(4): 335-342.
14. Johnson BA, Nunley JR. Treatment of seborrheic dermatitis. American family physician 2000; 61: 2703-10, 2713-4.
15. Mastrolonardo M, Diaferio A, Logroscino G. Seborrheic dermatitis, increased sebum excretion, and Parkinson’s disease: a survey of (im) possible links. Medical hypotheses 2003; 60: 907-911.
16. Emre S, Metin A, Demirseren, DD et al. The association of oxidative stress and disease activity in seborrheic dermatitis. Arch Dermatol Res 2012; 304: 683-687.
17. Roy D, Quiles J, Gaze DC et al. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart 2006: 92; 113-4.
18. Piva SJ, Duarte MM, Da Cruz IB et al. Ischemia-modified albumin as an oxidative stress biomarker in obesity. Clin Biochem 2011: 44; 345-7.
19. Ustun Y, Engin-Ustun Y, Ozturk O, Alanbay I, Yaman H. Ischemia-modified albumin as an oxidative stress marker in preeclampsia. J Matern Fetal Neonatal Med 2011: 24; 418-21.
20. Niwa Y, Mizushima Y. Neutrophil-potentiating factors released from stimulated lymphocytes; special reference to the increase in neutrophil-potentiating factors from streptococcus-stimulated lymphocytes of patients with Behçet’s disease. Clin Exp Immunol 1990: 79; 353-60.
21. Altunısık N, Türkmen D. Serum bilirubin, uric acid and albumin levels in patients with alopecia areata. Ege Journal of Medicine 2020; 59 (1): 1-6.
22. Keskin S, Aksu Arica D, Orem A, Akcan B, Mentese A, Bahadir S. Ischemia modified albumin: a useful marker for increased oxidative stress in Behçet’s disease. Mucosa 2019; 2(1): 19-27.
23. Omma A, Sandikci SC, Colak S, Tecer D, Yucel C, Ozbalkan Z. Serum calprotectin and ischemia modified albumin levels as markers of disease activity in Behçet’s disease. Postepy Dermatol Alergol 2018 Dec; 35(6): 609-613.
24. Valle Gottlieb MG, da Cruz IB, Duarte MM et al. Associations among metabolic syndrome, ischemia, inflammatory, oxidatives, and lipids biomarkers. J Clin Endocrinol Metab 2010: 95; 586- 91.
25. Duarte MM, Rocha JB, Moresco RN et al. Association between ischemia-modified albumin, lipids and inflammation biomarkers in patients with hypercholesterolemia. Clin Biochem 2009: 42; 666-71.
26. Kaefer M, Piva SJ, De Carvalho JA et al. Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. Clin Biochem 2010: 43; 450-4.
27. Atas H, Kocabıyık M, Gönül M, Öztürk Yasin, Kavutçu M. Usefulness of ischemia-modified albumin in predicting oxidative stress in patients with vitiligo. Biomarkers in Medicine 2017; 6:439-449.